| Sep 13 2023 |
New York’s Office of the Medicaid Inspector General Creates Abbreviated Self-Disclosure Process |
Mintz |
| Sep 13 2023 |
The “Meaningful Benefit” Requirement for NQTLs Under the Proposed MHPAEA Regulations |
McDermott Will & Emery |
| Sep 13 2023 |
Sua Sponte State Law Certification in Opioid MDL Appeal |
Squire Patton Boggs (US) LLP |
| Sep 12 2023 |
Congressional Republicans Solicit Comments from Health Stakeholders |
Squire Patton Boggs (US) LLP |
| Sep 12 2023 |
California’s Recent Proposed Regulations Include Significant Requirements for Health Care Transactions |
Greenberg Traurig, LLP |
| Sep 11 2023 |
CMS Announces Changes to ACO REACH Model |
Sheppard, Mullin, Richter & Hampton LLP |
| Sep 11 2023 |
Healthcare Preview For The Week Of: September 11, 2023 |
McDermott Will & Emery |
| Sep 11 2023 |
Expanding Existing Bereavement Leave Policies to Account for Fertility Related Losses |
Mintz |
| Sep 11 2023 |
FDA Issues Draft Guidance on Best Practices for Selecting Predicate Devices for 510(k) Notifications |
ArentFox Schiff LLP |
| Sep 8 2023 |
New York Proposes Regulations Expanding State’s Ability to Regulate Pbms |
McDermott Will & Emery |
| Sep 8 2023 |
Clinical Trials: Consent Process Clarified in New FDA Final Guidance |
Foley & Lardner LLP |
| Sep 8 2023 |
Takeaways from a Recent COBRA Notice Class Action Settlement |
McDermott Will & Emery |
| Sep 8 2023 |
FDA Issues Final Guidance on Informed Consent in Clinical Investigations |
McDermott Will & Emery |
| Sep 7 2023 |
Context is Key: FDA Sends a Strong Message About Efficacy Claims |
Sheppard, Mullin, Richter & Hampton LLP |
| Sep 7 2023 |
No More Surprise Medical Bills: Providers Score Yet Another Victory as Texas Court Again Vacates Provisions of Biden Administration’s Surprise Billing Regulations |
ArentFox Schiff LLP |
| Sep 7 2023 |
Joint Commission Issues Alert on Patient Safety After a Cyber-Attack |
Robinson & Cole LLP |
| Sep 7 2023 |
CMS Releases Draft Part One Guidance on the Maximum Monthly Cap on Cost-Sharing Payments Program to Part D Plans |
Mintz |
| Sep 7 2023 |
Public Workshop for OHCA’s Proposed Regulations Sparks Lively Discussion Among Industry Stakeholders |
Sheppard, Mullin, Richter & Hampton LLP |
| Sep 7 2023 |
USCIS Confirms Evidentiary Requirements for Physician National Interest Waiver |
Greenberg Traurig, LLP |
| Sep 7 2023 |
The ‘Data Evaluation Requirement’ for NQTLs Under the Newly Proposed MHPAEA Regulations |
McDermott Will & Emery |
| Sep 7 2023 |
Transformation in Nursing Home Care: HHS Proposes New Staffing Standards |
Nelson Mullins |
| Sep 6 2023 |
Buckle Up: Artificial Intelligence Accelerates Drug Discovery and Streamlines Patient Care |
Womble Bond Dickinson (US) LLP |
| Sep 6 2023 |
How Will Nevada’s Newest Restrictions on Mental and Physical Examinations Affect Your Claims? |
Wilson Elser Moskowitz Edelman & Dicker LLP |
| Sep 6 2023 |
Long Term Care Facilities Face Mandatory Minimum Staffing Requirements |
Sheppard, Mullin, Richter & Hampton LLP |
| Sep 6 2023 |
Decentralized Clinical Trials: Sponsor Responsibilities |
Foley & Lardner LLP |
| Sep 5 2023 |
Insights From The IBM 2023 Cost of a Data Breach Report |
Jackson Lewis P.C. |
| Sep 5 2023 |
California Expands Liability Under the FEHA to Business-Entity Agents |
Foley & Lardner LLP |
| Sep 5 2023 |
California’s Workplace Violence Prevention Bill Passes Assembly Appropriations Committee With New Amendments |
Ogletree, Deakins, Nash, Smoak & Stewart, P.C. |
| Sep 5 2023 |
Unpacking Averages: How Accurate Do Class II Medical Devices Need to Be to Obtain 510(k) Clearance? |
Epstein Becker & Green, P.C. |
| Sep 5 2023 |
Unpacking Averages: How Accurate Do Class II Medical Devices Need to Be to Obtain 510(k) Clearance? |
Epstein Becker & Green, P.C. |
| Sep 5 2023 |
ACA Affordability Updated: Rev. Proc. 2023-29 |
Jackson Lewis P.C. |
| Sep 5 2023 |
FDA Issues Final Guidance on Informed Consent for IRBs, Clinical Investigators, and Sponsors |
Epstein Becker & Green, P.C. |
| Sep 5 2023 |
State Regulation of Pharmacy Benefit Managers: Tenth Circuit Holds That ERISA and Medicare Part D Preempt Key Parts of Oklahoma PBM Law |
Epstein Becker & Green, P.C. |
| Sep 5 2023 |
Old North State Report – Sept. 5, 2023 |
Nelson Mullins |
| Sep 1 2023 |
CMS Names Its First Ten Negotiated Part D Drugs: Inflation Reduction Act Updates |
Epstein Becker & Green, P.C. |
